News AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:26 15/05/2026 BST			5-day change	1st Jan Change
13,632.00 ^GBX	-0.79%		+2.16%	-1.15%

11:36pm	Daiichi Sankyo, AstraZeneca get US approvals for Enhertu	AN
05-17	AstraZeneca's Breast Cancer Treatment Lands US FDA Nod for Two New Indications	MT

All News

Mentions Relevance

11:36pm	Daiichi Sankyo, AstraZeneca get US approvals for Enhertu	AN
05-17	AstraZeneca's Breast Cancer Treatment Lands US FDA Nod for Two New Indications	MT
05-16	ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer	BU
05-15	AstraZeneca : Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer	PU
05-14	AstraZeneca bladder cancer trial yields encouraging results	AN
05-14	Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial	BU
05-14	AstraZeneca immunotherapy for stomach cancer green lit for NHS use	AN
05-14	ASTRAZENECA : JP Morgan reiterates its Buy rating	ZD
05-14	AstraZeneca's bladder cancer drug yields encouraging test results	AN
05-14	AstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial	MT
05-14	AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial	RE
05-14	AstraZeneca says no new safety signals for Imfinzi with or without Imjudo plus Enfortumab Vedotin	RE
05-14	AstraZeneca Combo Therapy Shows Improved Event-free, Overall Survival in Bladder Cancer	MT
05-14	AstraZeneca : Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial	PU
05-14	AstraZeneca PLC Announces Imfinzi Plus Enfortumab Vedotin Improves Event-Free Survival And Overall Survival In Bladder Cancer	CI
05-13	ASTRAZENECA : Jefferies remains its Buy rating	ZD
05-13	AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making	MT
05-13	Astrazeneca Expands AI Partnership With Owkin Under Three-Year Licensing Deal	MT
05-13	Owkin Enters License Agreement With AstraZeneca	CI
05-12	AstraZeneca's Phase 3 Trial Shows Significant Results in Patients With Hypoparathyroidism	MT
05-12	AstraZeneca hails phase-3 trial results for hypoparathyroidism drug	AN
05-12	AstraZeneca : Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial	PU
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
05-07	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ